Loading
A phase 2 trial of Imlunestrant and Tamoxifen in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, now recruiting.
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer is a phase 2 interventional study registered as NCT07287098 by Eli Lilly and Company, with 600 participants planned, started 2026-05-13 and due to reach its primary completion in 2029-01. Interventions recorded: Imlunestrant, Goserelin and Tamoxifen 20 mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imlunestrant, Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/